BGLAP and obesity disorder: A clinical trial included people (without diabetes) with common obesity and people with one of the most common monogenic causes of obesity in humans, a mutation in the melanocortin‐4 receptor (MC4R).(44) They observed a 6% weight loss in both groups but no differences in markers of bone turnover (CTX, osteocalcin and P1NP) after 16 weeks of liraglutide treatment (neither in groups of between groups).